SLC1A5 and cancer: Recently, production of anti‐human ASCT2 mAbs was reported, and these mAbs suppressed glutamine‐dependent cancer cell growth.51 However, it remains unclear whether these mAbs have in vivo anti‐tumor activity against KRAS‐mutated cancers.